Superluminal Medicines, a Boston, MA-based company that uses generative biology, chemistry and machine learning approaches to create medicines, raised $120M in Series A funding.
The round was led by RA Capital Management with participation from existing investors Insight Partners, NVentures (NVIDIA’s venture capital arm), and Gaingels. New investors Catalio Capital Management, Eli Lilly and Company, and Cooley LLP joined in the financing, and Diamantis Xylas, MD of Catalio joined the Board of Directors.
The company intends to use the funds to support the progression of its lead program into clinical development and increase the number of small molecule drug discovery programs focused on high-value G protein-coupled receptor (GPCR) targets.
Led by CEO Cony D’Cruz, Superluminal Medicines is a generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Its platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Its discovery engine is powered by a pharmacokinetic and toxicology in silico prediction capability. The company’s proprietary pipeline validates its platform with initial programs focused on high-value GPCR targets.
The company’s board of directors includes Andrew Levin, MD, PhD, Partner and Managing Director at RA Capital Management; Dylan Morris PhD, Managing Director at Insight Partners; Diamantis Xylas MD, Partner and Co-Head of Investments at Catalio Capital Management and Cony D’Cruz, CEO of Superluminal Medicines.
FinSMEs
09/09/2024